Stock Analiz

China Pharma Holdings, Inc. CPHI

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$0.52Market cap $22M
Open the interactive analysis →

China Pharma Holdings, Inc. (CPHI) is a healthcare company listed in the US with a market value of about $22M. In the twelve months to June 30, 2026 it had revenue of $4M and net income of -$4M, a net margin of -114.3%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).

Key numbers: a price to free cash flow of 250.6, 5-year revenue growth of -18% a year, a 5-year average ROIC of -25%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 98% below the current price.

About China Pharma

China Pharma is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $22M in 2014 to $4M in 2025, a decline of about 14.1% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 3982% over three years (dilution for shareholders). It spends 7% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health3/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF250.6
P/S5.7
P/B0.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield0.4%
Shareholder yield0.0%
Intrinsic value vs. price−98%

Growth and quality

Revenue growth (1 yr)-8.5%
Revenue growth (5 yrs, per year)-17.5%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-61.9%
ROIC (5-yr avg.)-24.6%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$4M$4M$5M$7M$8M$10M$11M$11M$12M$13M$16M
Net income-$4M-$3M-$5M-$3M-$4M-$3M-$3M-$21M-$11M-$19M-$9M
Free cash flow—$88937-$444474-$711203-$811509-$687893-$909567$472309$2M$704737$3M
EPS (diluted)$-0.42$-0.74$-2.71$-9.10$-37.80$-37.00$-3.50$-24.00$-12.50$-22.00$-10.50
Net margin-114.3%-76.9%-104.6%-43.9%-49.0%-35.3%-26.4%-189.5%-87.2%-145.9%-59.0%
ROIC—-10.5%-35.1%-21.5%-34.5%-21.7%-15.3%-117.9%-28.1%-28.2%-10.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is China Pharma stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 98% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does China Pharma pay a dividend?

Not currently.

Is China Pharma a good stock to buy?

We do not give buy or sell advice. China Pharma scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.